Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Public ClinicalTrials.gov record NCT06191796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with advanced ccRCC or other advanced solid tumors. The main questions it aims to answer are: * The recommended doses (RDs) * The safety and tolerability * The PK and the preliminary efficacy
Study identification
- NCT ID
- NCT06191796
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 25 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 25, 2024 (Actual)
- Primary completion
- May 12, 2025 (Actual)
- Completion
- May 12, 2025 (Actual)
- Last update posted
- Jun 12, 2025
2024 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Site #8 | Los Angeles | California | 90033 | — |
| Exelixis Site #9 | Miami | Florida | 33176 | — |
| Exelixis Clinical Site #1 | Orlando | Florida | 32804 | — |
| Exelixis Site #11 | Tampa | Florida | 33612 | — |
| Exelixis Site #6 | Scarborough | Maine | 04074 | — |
| Exelixis Site #5 | St Louis | Missouri | 63110 | — |
| Exelixis Clinical Site #3 | New Hyde Park | New York | 11776 | — |
| Exelixis Site #14 | New York | New York | 10028 | — |
| Exelixis Site #13 | Shirley | New York | 11987 | — |
| Exelixis Site #15 | The Bronx | New York | 10469 | — |
| Exelixis Clinical Site #2 | Nashville | Tennessee | 37203 | — |
| Exelixis Clinical Site #16 | Salt Lake City | Utah | 84112 | — |
| Exelixis Site #4 | Spokane | Washington | 99208 | — |
| Exelixis Site #12 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06191796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06191796 live on ClinicalTrials.gov.